Another study reported that the activation of the PI3K/AKT pathway by EGCG protected the brain against amyloid-beta accumulation, which thereby slowed down Alzheimer’s disease progression (Yamamoto et al., 2017). This evidence concerns the gene AKT1 and early-onset autosomal dominant Alzheimer disease.